Yoshiyuki Meguro, Hironori Yamaguchi, Hideki Sasanuma, Kentaro Shimodaira, Yuichi Aoki, Takashi Chinen, Kazue Morishima, Hideyo Miyato, Atsushi Miki, Kazuhiro Endo, Alan Kawarai Lefor, Joji Kitayama, Naohiro Sata
Internal medicine (Tokyo, Japan) 2023年12月4日
The prognosis of patients with peritoneal metastases from pancreatic cancer is poor, largely due to massive ascites, which precludes systemic treatment. Two patients with a poor performance status and malignant ascites were treated with cell-free and concentrated ascites reinfusion therapy followed by combined chemotherapy with intraperitoneal paclitaxel, intravenous gemcitabine, and nab-paclitaxel. These patients achieved a survival of 19 and 36 weeks with a relatively good quality of life. Combined intraperitoneal paclitaxel and systemic chemotherapy may provide effective palliative management for some patients with peritoneal metastases from pancreatic cancer.
